BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vekemans J, Hasso-Agopsowicz M, Kang G, Hausdorff WP, Fiore A, Tayler E, Klemm EJ, Laxminarayan R, Srikantiah P, Friede M, Lipsitch M. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework. Clin Infect Dis 2021;73:e1011-7. [PMID: 33493317 DOI: 10.1093/cid/ciab062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Arístegui J, Alfayate-Miguelez S, Carazo-Gallego B, Garrote E, Díaz-Munilla L, Mendizabal M, Méndez-Hernández M, Doménech E, Ferrer-Lorente B, Unsaín-Mancisidor M, Ramos-Amador JT, Illán-Ramos M, Croche-Santander B, Centeno Malfaz F, Rodríguez-Suárez J, Cotarelo Suárez M, San-Martín M, Ruiz-Contreras J. Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013-2018). Hum Vaccin Immunother 2022;18:2046961. [PMID: 35435807 DOI: 10.1080/21645515.2022.2046961] [Reference Citation Analysis]
2 Maclennan CA, Steele AD. Frontiers in Shigella Vaccine Development. Vaccines 2022;10:1536. [DOI: 10.3390/vaccines10091536] [Reference Citation Analysis]
3 Rogawski McQuade ET, Brennhofer SA, Elwood SE, McMurry TL, Lewnard JA, Mduma ER, Shrestha S, Iqbal N, Bessong PO, Kang G, Kosek M, Lima AAM, Ahmed T, Liu J, Houpt ER, Platts-Mills JA. Frequency of bystander exposure to antibiotics for enteropathogenic bacteria among young children in low-resource settings. Proc Natl Acad Sci U S A 2022;119:e2208972119. [PMID: 36037372 DOI: 10.1073/pnas.2208972119] [Reference Citation Analysis]
4 Maclennan CA, Grow S, Ma L, Steele AD. The Shigella Vaccines Pipeline. Vaccines 2022;10:1376. [DOI: 10.3390/vaccines10091376] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Klimko CP, Shoe JL, Rill NO, Hunter M, Dankmeyer JL, Talyansky Y, Schmidt LK, Orne CE, Fetterer DP, Biryukov SS, Burtnick MN, Brett PJ, Deshazer D, Cote CK. Layered and integrated medical countermeasures against Burkholderia pseudomallei infections in C57BL/6 mice. Front Microbiol 2022;13:965572. [DOI: 10.3389/fmicb.2022.965572] [Reference Citation Analysis]
6 Ikhimiukor OO, Odih EE, Donado-godoy P, Okeke IN. A bottom-up view of antimicrobial resistance transmission in developing countries. Nat Microbiol. [DOI: 10.1038/s41564-022-01124-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Maldonado E, Morales-pison S, Urbina F, Solari A. Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids. Vaccines 2022;10:587. [DOI: 10.3390/vaccines10040587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lewnard JA, Fries LF, Cho I, Chen J, Laxminarayan R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc Natl Acad Sci U S A 2022;119:e2112410119. [PMID: 35286196 DOI: 10.1073/pnas.2112410119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Holm M, Zellweger RM, Poudyal N, Smith KH, Joh HS, Marks F. Measuring the Link Between Vaccines and Antimicrobial Resistance in Low Resource Settings – Limitations and Opportunities in Direct and Indirect Assessments and Implications for Impact Studies. Front Trop Dis 2022;3:805833. [DOI: 10.3389/fitd.2022.805833] [Reference Citation Analysis]
10 Hausdorff WP, Scheele S, Giersing BK. What Drives the Value of a Shigella Vaccine? Vaccines 2022;10:282. [DOI: 10.3390/vaccines10020282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Wójcik-Bojek U, Różalska B, Sadowska B. Staphylococcus aureus-A Known Opponent against Host Defense Mechanisms and Vaccine Development-Do We Still Have a Chance to Win? Int J Mol Sci 2022;23:948. [PMID: 35055134 DOI: 10.3390/ijms23020948] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Marchetti F, Prato R, Viale P. Survey among Italian experts on existing vaccines' role in limiting antibiotic resistance. Hum Vaccin Immunother 2021;:1-8. [PMID: 34591738 DOI: 10.1080/21645515.2021.1969853] [Reference Citation Analysis]
13 Vyse A, Campling J, Czudek C, Ellsbury G, Mendes D, Reinert RR, Slack M. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Rev Vaccines 2021;20:1311-25. [PMID: 34550850 DOI: 10.1080/14760584.2021.1984888] [Reference Citation Analysis]
14 Andrejko K, Whittles LK, Lewnard JA. Health-economic value of vaccination against group A Streptococcus in the United States. Clin Infect Dis 2021:ciab597. [PMID: 34192307 DOI: 10.1093/cid/ciab597] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cars O, Chandy SJ, Mpundu M, Peralta AQ, Zorzet A, So AD. Resetting the agenda for antibiotic resistance through a health systems perspective. Lancet Glob Health 2021;9:e1022-7. [PMID: 34143980 DOI: 10.1016/S2214-109X(21)00163-7] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
16 Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, Saleem Z, Sneddon J, Hoxha I, Islam S, Mwita J, do Nascimento RCRM, Dias Godói IP, Niba LL, Amu AA, Acolatse J, Incoom R, Sefah IA, Opanga S, Kurdi A, Chikowe I, Khuluza F, Kibuule D, Ogunleye OO, Olalekan A, Markovic-Pekovic V, Meyer JC, Alfadl A, Phuong TNT, Kalungia AC, Campbell S, Pisana A, Wale J, Seaton RA. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life (Basel) 2021;11:528. [PMID: 34200116 DOI: 10.3390/life11060528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]